Betamethasone Acetate Market Size to Exceed USD 672.8 Mn by 2032

The Betamethasone Acetate Market, estimated at USD 484.6 Mn in 2025, is expected to exhibit a CAGR of 4.8% and reach USD 672.8 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

The key players in the market are focusing on adoption of inorganic growth strategies such as partnerships, and collaborations, in order to strengthen their market presence in the global betamethasone acetate market is expected to drive the market growth over the forecast period. For instance, in November 2025, Sanofi, a pharmaceutical company, announced the acquisition of Kamron Holdings, Inc., a biopharmaceutical company. The acquisition helps Sanofi to strengthen the expansion for the General Medicines portfolio including betamethasone acetate products.

Global Betamethasone Acetate Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025," or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and health of every country in the world.

The COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others are facing problems with regards to the transportation of drugs from one place to another.

The COVID-19 had a positive impact on the global betamethasone acetate market, owing to its application in the COVID-19-pandemic-associated symptoms such as muscle pain. For instance, in July 2025, according to data published by Radiological society of North America, Department of Anesthesiology, Critical Care and Pain Medicine, Boston’s Children Hospital USA, performed study of 1960 adults undergoing image-guided corticosteroid injections for pain management during the COVID-19 pandemic from April 2025 to February 2025, the rate of symptomatic COVID-19 was lower than that of the state population. The betamethasone sodium phosphate and acetate injectable suspension (6 mg/mL, 6–21 mg) corticosteroids doses were used to reduce muscle pain. Thus, COVID-19 had a positive impact on the betamethasone acetate market.

Global Betamethasone Acetate Market: Key Developments

In September 2025, McKesson Corporation, a provider of healthcare services, announced the partnership with CVS Health, an American healthcare company to distribute pharmaceuticals products. The partnership helps to increase McKesson Corporation distribution network worldwide.

Browse 51 Market Data Tables and 54 Figures spread through 203 Pages and in-depth TOC on “Global Betamethasone Acetate Market”- Forecast to 2032, by Formulation (Suspension, Ointment, and Gel), by Route of Administration (Intramuscular, Intra-articular, and Intradermal), by Application (Respiratory Disease, Renal Disease, Gastrointestinal Disease, Ophthalmic Disease, Dermatological Disease, and Others), by Age Group (Pediatric and Geriatric), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/betamethasone-acetate-market-5481

Key Takeaways of the Global Betamethasone Acetate Market:

The global betamethasone acetate market is expected to exhibit a CAGR of 4.8% during the forecast period. The increasing research and development activities by key players in the market to expand product portfolio is expected to drive the segment growth over the forecast period. For instance, in January 2025, according to data published by Journal of clinical medicine, Department of Neonatology, Regional University Hospital of Malaga, Spain performed a retrospective cohort study including preterm infants ≤34 weeks gestational age at birth and ≤1500 g, admitted to an Neonatal Intensive Care Unit (NICU) IIIC level in a tertiary hospital from 2015 to 2025. The tertiary hospital with a Neonatal Intensive Care Unit (NICU) level IIIC, maturation with prenatal corticosteroids is performed with betamethasone (50% in the acetate form and 50% in the phosphate form). The main objective of this study was to determine neonatal serious outcomes (mortality and serious sequelae) in preterm infants who received two doses of betamethasone 12 h apart compared to preterm infants who received the full standard dose.
Among route of administration, intramuscular segment is estimated to hold a dominant position in the global betamethasone acetate market over the forecast period. Owing to the increasing prevalence of renal disease. For instance, in June 2025, according to data provided by the U.S. Department of Health and Human Services, the number of patients with end-stage renal disease in 2025 was 13,636, a 2.3% increase since 2025.
Among regions, North America, is expected to be the most dominant region in the global betamethasone acetate market, owing to increasing research and development activities by key players in the market to expand product portfolio is expected to drive the segment growth over the forecast period. For instance, in November 2025, Reno Orthopedic Center in the U.S., initiated clinical trial on effect of ZILRETTA versus CELESTONE on quality of life, pain, neuromuscular function, and physical performance. The purpose of this study is to examine the pre, post, and follow up effects of a single ZILRETTA knee injection vs a single CELESTONE SOLUSPAN knee injection on physiological measure of self-reported quality of life, pain, physical function, and physical performance in individuals with osteoarthritis (OA) knee pain. The completion date of study was April 2025.
Major players operating in the global betamethasone acetate market include Merck & Co., Inc., American Regent, Inc., McKesson Medical-Surgical Inc., GNHIndia.com, Lexicon Medical Supply, Medline Industries, Inc., Caspian Tamin Pharmaceutical Co., Sandoz Canada Inc, NorthWestPharmacy.com Inc., Medisca Inc, Exela Pharma Sciences, LLC, Sanofi Pasteur Inc., Sorrento Therapeutics Inc.